MPI – Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world’s largest cancer congress ASCO 2018

Hoersholm, Denmark, June 1, 2018 – Medical Prognosis Institute A/S (“MPI”) hereby announces that clinical data on PARP inhibitor 2X-121 and DRP response prediction validation is to be presented on the world’s largest cancer congress ASCO 2018 on June 1st 2018.

Oncology Venture – MPI’s drug development arm – in-licensed the active PARP inhibitor E7449 now called 2X-121 from Eisai in Q2 2017 and present clinical data as well as data demonstrating validation of Oncology Ventures novel DRP®s ability to identify the patients who will benefit from 2X-121 therapy.

We are very proud that we can already now present our clinical data with our PARP inhibitor 2X-121 and our DRP®. 2X-121 is active and our DRP® shows excellent prediction in a field with very successful competing products and a challenge to obtain precision”, says Peter Buhl Jensen, M.D., CEO of MPI. “The DRP predicts response independent of BRCA mutations and may allow a more precise targeting of response, said Peter Buhl Jensen. 

The oral presentation will be given by Dr Ruth Plummer who is the principal investigator in the first 2X-121 clinical trial.

Session: Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics

Date: June 1, 2018

Time: 4:09pm CDT

Location: S406

Abstract No.: 224139

Abstract Title:                             First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP®) mRNA biomarker. http://abstracts.asco.org/214/AbstView_214_224139.html

For further information, please contact:
CEO, Peter Buhl Jensen, MD, Ph.D.                                                           Ulla Hald Buhl, IR & Communication
E-mail: pbj@medical-prognosis.com                                                          E-mail: uhb@medical-prognosis.com
Telephone: +45 21 60 89 22                                                                                        Telephone +45 21 70 10 49

About MPI’s multiple biomarker called Drug Response Predictor – DRP®
MPI’s DRP® is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP® has been tested in 37 trials, where 29 trials showed that drug-specific DRP® Biomarkers could predict which patients responded well to the treatment. The DRP® platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP® method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP® builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP® is a Big Data tool based on messenger RNA. The DRP® platform can be used in all cancer types, and has been patented for more than 70 anti-cancer drugs in the US.

About MPI
Medical Prognosis Institute is a publicly traded international company specialized in improving cancer patients’ lives by developing Personalized Medicine using its unique DRP® technology. MPI’s exceptional opportunity to personalize cancer treatment begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP® tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark. MPI has ownership of Oncology Venture (Publ) a spinout with three anti-cancer drugs in pipeline entered and of the privately hold Special Purpose Vehicles, 2X Oncology Inc. and OV-SPV2 Aps with four products in pipeline.

On the May 30, 2018, MPI and Oncology Ventures respective general assemblies decided to merge. Trading in the Oncology Venture share continues the next couple of months and all OV shares will – when the merger is finalized – give 1,8524 MPI shares.

This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 1, 2018.

Certified Adviser: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

Attachment